Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.68 |
| ▸ | CA2 | P00918 | 13/20 | 0.68 |
| ▸ | CA9 | Q16790 | 13/20 | 0.68 |
| ▸ | CA12 | O43570 | 7/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426705 | 0.90 | CA9 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13219607 | 0.89 | CA1 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13815114 | 0.88 | CA1 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12185092 | 0.88 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL1638181 | 0.88 | CA1 (0.75) | CA1CA2CA9CA12CA14 | |
| SCHEMBL18387321 | 0.87 | CA9 (0.66) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22203877 | 0.87 | CA1 (0.66) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14164948 | 0.86 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21183301 | 0.86 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21282083 | 0.86 | CA1 (0.70) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170191935-A1 | FLUORESCENT NANOSENSORS AND USES THEREOF | UNIVERSITé LAVAL (CA) | 2017-07-06 | — | — | US | disclosed |
| US-20140301951-A1 | POROUS NANOPARTICLE SUPPORTED LIPID NANOSTRUCTURES | SANDIA CORPORATION | 2014-10-09 | — | — | US | disclosed |
| US-8734816-B2 | Porous nanoparticle supported lipid bilayer nanostructures | STC.UNM (US) | 2014-05-27 | — | — | US | disclosed |
| US-20110268791-A1 | POROUS NANOPARTICLE SUPPORTED LIPID BILAYER NANOSTRUCTURES | THE UNITED STATES OF AMERICA | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268791-A1 | POROUS NANOPARTICLE SUPPORTED LIPID BILAYER NANOSTRUCTURES | EPCAM, NPC1L1, CD47 | CA1 286/4885CA2 942/4885CA9 362/4885 |
| US-20140301951-A1 | POROUS NANOPARTICLE SUPPORTED LIPID NANOSTRUCTURES | EPCAM, LIPA, NPC1L1 | CA1 224/4885CA2 986/4885CA9 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.